Small-molecule inhibition of inflammatory β-cell death

Diabetes, Obesity and Metabolism

Volumn 15, Issue S3, 2013, Pages 176-184

  Lundh, M ^a,b   Scully, S S ^a   Mandrup Poulsen, T ^b,c   Wagner, B K ^a  

^a BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Apoptosis; Glucolipotoxicity; Glucotoxicity; Inflammation; Lipotoxicity; Proinflammatory cytokines; Small molecules; cell

Indexed keywords

ALPHA TOCOPHEROL; ALSTERPAULLONE; BRD 0476; CANAKINUMAB; CD3 ANTIBODY; CYTOKINE; GLIBENCLAMIDE; IMATINIB; METFORMIN; REACTIVE OXYGEN METABOLITE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; ROSIGLITAZONE; SUPPRESSOR FACTOR; TRICHOSTATIN A; TUNICAMYCIN; UNCLASSIFIED DRUG; VORINOSTAT;

APOPTOSIS; CELL DEATH; CELL LOSS; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN SENSITIVITY; LIPOTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; REVIEW;

APOPTOSIS; GLUCOLIPOTOXICITY; GLUCOTOXICITY; INFLAMMATION; LIPOTOXICITY; PROINFLAMMATORY CYTOKINES; SMALL-MOLECULES; Β-CELL;

ANIMALS; ANTI-INFLAMMATORY AGENTS; APOPTOSIS; CELL DEATH; CYTOKINES; DOWN-REGULATION; HUMANS; HYPOGLYCEMIC AGENTS; INFLAMMATION; INSULIN-SECRETING CELLS; SMALL MOLECULE LIBRARIES;

EID: 84883509791     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12158     Document Type: Review

References (96)

1. Klinke DJ. Extent of beta cell destruction is important but insufficient to predict the onset of type 1 diabetes mellitus. PLoS One 2008; 3: e1374.
2. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003; 52: 102-110.
3. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011; 11: 98-107.
4. Eizirik DL, Mandrup-Poulsen T. A choice of death-the signal-transduction of immune-mediated beta-cell apoptosis. Diabetologia 2001; 44: 2115-2133.
5. Donath MY, Storling J, Berchtold LA, Billestrup N, Mandrup-Poulsen T. Cytokines and beta-cell biology: from concept to clinical translation. Endocr Rev 2008; 29: 334-350.
6. Mandrup-Poulsen T, Pickersgill LMS, Donath M. Blockade of interleukin-1 in Type 1 diabetes mellitus. Nat Rev Endocrinol 2010; 6: 158-166.
7. Larsen CM, Faulenbach M, Vaag A et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007; 356: 1517-1526.
8. Bonny C, Oberson A, Negri S, Sauser C, Schorderet DF. Cell-permeable peptide inhibitors of JNK: novel blockers of beta-cell death. Diabetes 2001; 50: 77-82.
9. Borsello T, Clarke PG, Hirt L et al. A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia. Nat Med 2003; 9: 1180-1186.
10. Sandberg JO, Andersson A, Eizirik DL, Sandler S. Interleukin-1 receptor antagonist prevents low dose streptozotocin induced diabetes in mice. Biochem Biophys Res Commun 1994; 202: 543-548.
11. Ablamunits V, Henegariu O, Hansen JB et al. Synergistic reversal of type 1 diabetes in NOD mice with anti-CD3 and interleukin-1 blockade: evidence of improved immune regulation. Diabetes 2012; 61: 145-154.
12. Moran A, Bundy B, Becker DJ et al. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet 2013; 381: 1905-1915.
13. Cavelti-Weder C, Babians-Brunner A, Keller C et al. Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes Care 2012; 35: 1654-1662.
14. Sloan-Lancaster J, Abu-Raddad E, Polzer J et al. Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1β antibody, in patients with type 2 diabetes. Diabetes Care 2013; DOI:10.2337/dc12-1835 [Epub 20 Mar 2013].
15. Larsen CM, Faulenbach M, Vaag A, Ehses JA, Donath MY, Mandrup-Poulsen T. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 2009; 32: 1663-1668.
16. Akeson AL, Woods CW, Hsieh LC et al. AF12198, a novel low molecular weight antagonist, selectively binds the human type I interleukin (IL)-1 receptor and blocks in vivo responses to IL-1. J Biol Chem 1996; 271: 30517-30523.
17. Quiniou C, Sapieha P, Lahaie I et al. Development of a novel noncompetitive antagonist of IL-1 receptor. J Immunol 2008; 180: 6977-6987.
18. Maedler K, Sergeev P, Ris F et al. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest 2002; 110: 851-860.
19. Masters SL, Dunne A, Subramanian SL et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1beta in type 2 diabetes. Nat Immunol 2010; 11: 897-904.
20. Cardozo AK, Heimberg H, Heremans Y et al. A comprehensive analysis of cytokine-induced and nuclear factor-kappa B-dependent genes in primary rat pancreatic beta-cells. J Biol Chem 2001; 276: 48879-48886.
21. Kim S, Millet I, Kim HS et al. NF-kappa B prevents beta cell death and autoimmune diabetes in NOD mice. Proc Natl Acad Sci U S A 2007; 104: 1913-1918.
22. Heimberg H, Heremans Y, Jobin C et al. Inhibition of cytokine-induced NF-kappaB activation by adenovirus-mediated expression of a NF-kappaB super-repressor prevents beta-cell apoptosis. Diabetes 2001; 50: 2219-2224.
23. Lam LT, Davis RE, Pierce J et al. Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin Cancer Res 2005; 11: 28-40.
24. Castro AC, Dang C, Soucy F et al. Novel IKK inhibitors: beta-carbolines. Bioorg Med Chem Lett 2003; 13: 2419-2422.
25. Manuvakhova MS, Johnson GG, White MC et al. Identification of novel small molecule activators of nuclear factor-kappaB with neuroprotective action via high-throughput screening. J Neurosci Res 2011; 89: 58-72.
26. Miller SC, Huang R, Sakamuru S et al. Identification of known drugs that act as inhibitors of NF-kappaB signaling and their mechanism of action. Biochem Pharmacol 2010; 79: 1272-1280.
27. Larsen L, Tonnesen M, Ronn SG et al. Inhibition of histone deacetylases prevents cytokine-induced toxicity in beta cells. Diabetologia 2007; 50: 779-789.
28. Dahllof MS, Christensen DP, Lundh M et al. The lysine deacetylase inhibitor givinostat inhibits beta-cell IL-1beta induced IL-1beta transcription and processing. Islets 2012; 4: 417-422.
29. Patel T, Patel V, Singh R, Jayaraman S. Chromatin remodeling resets the immune system to protect against autoimmune diabetes in mice. Immunol Cell Biol 2011; 89: 640-649.
30. Cabrera M, Colvin SC, Tersey SA, Maier B, Nadler JL, Mirmira RG. Effects of combination therapy with dipeptidyl peptidase-IV and histone deacetylase inhibitors in the NOD Mouse model of type 1 diabetes. Clinical Exp Immunol 2013; 172: 375-382.
31. Lundh M, Christensen DP, Rasmussen DN et al. Lysine deacetylases are produced in pancreatic beta cells and are differentially regulated by proinflammatory cytokines. Diabetologia 2010; 53: 2569-2578.
32. Chou DH, Holson EB, Wagner FF et al. Inhibition of histone deacetylase 3 protects beta cells from cytokine-induced apoptosis. Chem Biol 2012; 19: 669-673.
33. Lundh M, Christensen DP, Damgaard NM et al. Histone deacetylases 1 and 3 but not 2 mediate cytokine-induced beta cell apoptosis in INS-1 cells and dispersed primary islets from rats and are differentially regulated in the islets of type 1 diabetic children. Diabetologia 2012; 55: 2421-2431.
34. Chen L, Fischle W, Verdin E, Greene WC. Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science 2001; 293: 1653-1657.
35. Kiernan R, Bres V, Ng RW et al. Post-activation turn-off of NF-kappa B-dependent transcription is regulated by acetylation of p65. J Biol Chem 2003; 278: 2758-2766.
36. Chou DH, Bodycombe NE, Carrinski HA et al. Small-molecule suppressors of cytokine-induced beta-cell apoptosis. ACS Chem Biol 2010; 5: 729-734.
37. Fang X, Yu SX, Lu Y, Bast RC Jr, Woodgett JR, Mills GB. Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc Natl Acad Sci U S A 2000; 97: 11960-11965.
38. Jambal P, Masterson S, Nesterova A et al. Cytokine-mediated down-regulation of the transcription factor cAMP-response element-binding protein in pancreatic beta-cells. J Biol Chem 2003; 278: 23055-23065.
39. Storling J, Binzer J, Andersson AK et al. Nitric oxide contributes to cytokine-induced apoptosis in pancreatic beta cells via potentiation of JNK activity and inhibition of Akt. Diabetologia 2005; 48: 2039-2050.
40. Nielsen TE, Schreiber SL. Towards the optimal screening collection: a synthesis strategy. Angew Chem Int Ed Engl 2008; 47: 48-56.
41. Chou DH, Duvall JR, Gerard B et al. Synthesis of a novel suppressor of beta-cell apoptosis via diversity-oriented synthesis. ACS Med Chem Lett 2011; 2: 698-702.
42. Hagerkvist R, Sandler S, Mokhtari D, Welsh N. Amelioration of diabetes by imatinib mesylate (Gleevec): role of beta-cell NF-kappaB activation and anti-apoptotic preconditioning. FASEB J 2007; 21: 618-628.
43. Louvet C, Szot GL, Lang J et al. Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci U S A 2008; 105: 18895-18900.
44. Mokhtari D, Welsh N. Potential utility of small tyrosine kinase inhibitors in the treatment of diabetes. Clin Sci (Lond) 2010; 118: 241-247.
45. Ito Y, Pandey P, Mishra N et al. Targeting of the c-Abl tyrosine kinase to mitochondria in endoplasmic reticulum stress-induced apoptosis. Mol Cell Biol 2001; 21: 6233-6242.
46. Cardozo AK, Ortis F, Storling J et al. Cytokines downregulate the sarcoendoplasmic reticulum pump Ca2+ ATPase 2b and deplete endoplasmic reticulum Ca2+, leading to induction of endoplasmic reticulum stress in pancreatic beta-cells. Diabetes 2005; 54: 452-461.
47. Marhfour I, Lopez XM, Lefkaditis D et al. Expression of endoplasmic reticulum stress markers in the islets of patients with type 1 diabetes. Diabetologia 2012; 55: 2417-2420.
48. Huang CJ, Lin Y, Haataja L et al. High expression rates of human islet amyloid polypeptide induce endoplasmic reticulum stress mediated beta-cell apoptosis, a characteristic of humans with type 2 but not type 1 Diabetes. Diabetes 2007; 56: 2016-2027.
49. Lenzen S, Drinkgern J, Tiedge M. Low antioxidant enzyme gene expression in pancreatic islets compared with various other mouse tissues. Free Radic Biol Med 1996; 20: 463-466.
50. Lenzen S. Oxidative stress: the vulnerable beta-cell. Biochem Soc Trans 2008; 36: 343-347.
51. Cetkovic-Cvrlje M, Eizirik DL. TNF-alpha and IFN-gamma potentiate the deleterious effects of IL-1 beta on mouse pancreatic islets mainly via generation of nitric oxide. Cytokine 1994; 6: 399-406.
52. Gehrmann W, Elsner M, Lenzen S. Role of metabolically generated reactive oxygen species for lipotoxicity in pancreatic beta-cells. Diabetes Obes Metab 2010; 12(Suppl. 2): 149-158.
53. Robertson RP, Harmon J, Tran O, Tanaka Y, Takahashi H. Glucose toxicity in beta-cells: type 2 Diabetes, good radicals gone bad, and the glutathione connection. Diabetes 2003; 52: 581-587.
54. Tanaka Y, Gleason CE, Tran PO, Harmon JS, Robertson RP. Prevention of glucose toxicity in HIT-T15 cells and Zucker diabetic fatty rats by antioxidants. Proc Natl Acad Sci U S A 1999; 96: 10857-10862.
55. Kaneto H, Kajimoto Y, Miyagawa J et al. Beneficial effects of antioxidants in diabetes: possible protection of pancreatic beta-cells against glucose toxicity. Diabetes 1999; 48: 2398-2406.
56. Cotgreave IA. N-acetylcysteine: pharmacological considerations and experimental and clinical applications. Adv Pharmacol 1997; 38: 205-227.
57. Giardino I, Fard AK, Hatchell DL, Brownlee M. Aminoguanidine inhibits reactive oxygen species formation, lipid peroxidation, and oxidant-induced apoptosis. Diabetes 1998; 47: 1114-1120.
58. Edelstein D, Brownlee M. Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine. Diabetes 1992; 41: 26-29.
59. Mohseni Salehi Monfared SS, Larijani B, Abdollahi M. Islet transplantation and antioxidant management: a comprehensive review. World J Gastroenterol 2009; 15: 1153-1161.
60. Zhang Y, Zhen W, Maechler P, Liu D. Small molecule kaempferol modulates PDX-1 protein expression and subsequently promotes pancreatic beta-cell survival and function via CREB. J Nutr Biochem 2013; 24: 638-646.
61. Kaneto H, Fujii J, Myint T et al. Reducing sugars trigger oxidative modification and apoptosis in pancreatic beta-cells by provoking oxidative stress through the glycation reaction. Biochem J 1996; 320: 855-863.
62. Xiao C, Giacca A, Lewis GF. Oral taurine but not N-acetylcysteine ameliorates NEFA-induced impairment in insulin sensitivity and beta cell function in obese and overweight, non-diabetic men. Diabetologia 2008; 51: 139-146.
63. Suksomboon N, Poolsup N, Sinprasert S. Effects of vitamin E supplementation on glycaemic control in type 2 diabetes: systematic review of randomized controlled trials. J Clin Pharm Ther 2011; 36: 53-63.
64. Suksomboon N, Poolsup N, Boonkaew S, Suthisisang CC. Meta-analysis of the effect of herbal supplement on glycemic control in type 2 diabetes. J Ethnopharmacol 2011; 137: 1328-1333.
65. Hansen JB, Tonnesen MF, Madsen AN et al. Divalent metal transporter 1 regulates iron-mediated ROS and pancreatic beta cell fate in response to cytokines. Cell Metab 2012; 16: 449-461.
66. Ellervik C, Mandrup-Poulsen T, Andersen HU et al. Elevated transferrin saturation and risk of diabetes: three population-based studies. Diabetes Care 2011; 34: 2256-2258.
67. El-Assaad W, Buteau J, Peyot ML et al. Saturated fatty acids synergize with elevated glucose to cause pancreatic beta-cell death. Endocrinology 2003; 144: 4154-4163.
68. Carpentier A, Mittelman SD, Lamarche B, Bergman RN, Giacca A, Lewis GF. Acute enhancement of insulin secretion by FFA in humans is lost with prolonged FFA elevation. Am J Physiol 1999; 276: E1055-E1066.
69. Kashyap S, Belfort R, Gastaldelli A et al. A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes 2003; 52: 2461-2474.
70. Eizirik DL, Cardozo AK, Cnop M. The role for endoplasmic reticulum stress in diabetes mellitus. Endocr Rev 2008; 29: 42-61.
71. Poitout V, Robertson RP. Glucolipotoxicity: fuel excess and beta-cell dysfunction. Endocr Rev 2008; 29: 351-366.
72. Mussmann R, Geese M, Harder F et al. Inhibition of GSK3 promotes replication and survival of pancreatic beta cells. J Biol Chem 2007; 282: 12030-12037.
73. Stukenbrock H, Mussmann R, Geese M et al. 9-cyano-1-azapaullone (cazpaullone), a glycogen synthase kinase-3 (GSK-3) inhibitor activating pancreatic beta cell protection and replication. J Med Chem 2008; 51: 2196-2207.
74. Stein J, Milewski WM, Hara M, Steiner DF, Dey A. GSK-3 inactivation or depletion promotes beta-cell replication via down regulation of the CDK inhibitor, p27 (Kip1). Islets 2011; 3: 21-34.
75. Wagman AS, Johnson KW, Bussiere DE. Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetes. Curr Pharm Des 2004; 10: 1105-1137.
76. Xu G, Chen J, Jing G, Shalev A. Preventing beta-cell loss and diabetes with calcium channel blockers. Diabetes 2012; 61: 848-856.
77. Chen J, Saxena G, Mungrue IN, Lusis AJ, Shalev A. Thioredoxin-interacting protein: a critical link between glucose toxicity and beta-cell apoptosis. Diabetes 2008; 57: 938-944.
78. Chen J, Hui ST, Couto FM et al. Thioredoxin-interacting protein deficiency induces Akt/Bcl-xL signaling and pancreatic beta-cell mass and protects against diabetes. FASEB J 2008; 22: 3581-3594.
79. Chen J, Fontes G, Saxena G, Poitout V, Shalev A. Lack of TXNIP protects against mitochondria-mediated apoptosis but not against fatty acid-induced ER stress-mediated beta-cell death. Diabetes 2010; 59: 440-447.
80. Lerner AG, Upton JP, Praveen PV et al. IRE1alpha induces thioredoxin-interacting protein to activate the NLRP3 inflammasome and promote programmed cell death under irremediable ER stress. Cell Metab 2012; 16: 250-264.
81. Oslowski CM, Hara T, O'Sullivan-Murphy B et al. Thioredoxin-interacting protein mediates ER stress-induced beta cell death through initiation of the inflammasome. Cell Metab 2012; 16: 265-273.
82. Zhou R, Tardivel A, Thorens B, Choi I, Tschopp J. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol 2010; 11: 136-140.
83. Patane G, Piro S, Rabuazzo AM, Anello M, Vigneri R, Purrello F. Metformin restores insulin secretion altered by chronic exposure to free fatty acids or high glucose: a direct metformin effect on pancreatic beta-cells. Diabetes 2000; 49: 735-740.
84. Lupi R, Del GS, Fierabracci V et al. Lipotoxicity in human pancreatic islets and the protective effect of metformin. Diabetes 2002; 51(Suppl. 1): S134-S137.
85. Kefas BA, Cai Y, Kerckhofs K et al. Metformin-induced stimulation of AMP-activated protein kinase in beta-cells impairs their glucose responsiveness and can lead to apoptosis. Biochem Pharmacol 2004; 68: 409-416.
86. Lablanche S, Cottet-Rousselle C, Lamarche F et al. Protection of pancreatic INS-1 beta-cells from glucose- and fructose-induced cell death by inhibiting mitochondrial permeability transition with cyclosporin A or metformin. Cell Death Dis 2011; 2: e134.
87. Li N, Song J, Zhang L et al. Activation of the AMPK-FOXO3 pathway reduces fatty acid-induced increase in intracellular reactive oxygen species by upregulating thioredoxin. Diabetes 2009; 58: 2246-2257.
88. Raji A, Seely EW, Bekins SA, Williams GH, Simonson DC. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care 2003; 26: 172-178.
89. Ovalle F, Bell DS. Effect of rosiglitazone versus insulin on the pancreatic beta-cell function of subjects with type 2 diabetes. Diabetes Care 2004; 27: 2585-2589.
90. Higa M, Zhou YT, Ravazzola M, Baetens D, Orci L, Unger RH. Troglitazone prevents mitochondrial alterations, beta cell destruction, and diabetes in obese prediabetic rats. Proc Natl Acad Sci U S A 1999; 96: 11513-11518.
91. Finegood DT, McArthur MD, Kojwang D et al. Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. Diabetes 2001; 50: 1021-1029.
92. Han SJ, Kang ES, Hur KY et al. Rosiglitazone inhibits early stage of glucolipotoxicity-induced beta-cell apoptosis. Horm Res 2008; 70: 165-173.
93. Cnop M, Hannaert JC, Pipeleers DG. Troglitazone does not protect rat pancreatic beta cells against free fatty acid-induced cytotoxicity. Biochem Pharmacol 2002; 63: 1281-1285.
94. Shimabukuro M, Zhou YT, Lee Y, Unger RH. Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats. J Biol Chem 1998; 273: 3547-3550.
95. Kim EK, Kwon KB, Koo BS et al. Activation of peroxisome proliferator-activated receptor-gamma protects pancreatic beta-cells from cytokine-induced cytotoxicity via NF kappaB pathway. Int J Biochem Cell Biol 2007; 39: 1260-1275.
96. Kim JW, Yang JH, Park HS et al. Rosiglitazone protects the pancreatic beta-cell death induced by cyclosporine A. Biochem Biophys Res Commun 2009; 390: 763-768.